NRx Pharmaceuticals Inc Cash Flow-to-Debt Ratio
NRx Pharmaceuticals Inc cash flow-to-debt ratio. NRx Pharmaceuticals Inc (NRXPW) has a Cash Flow-to-Debt Ratio of -0.17x as of March 2026, meaning its operating cash flow of $-4.29 Million could theoretically repay 0% of its total liabilities ($25.72 Million) in one year. Check NRx Pharmaceuticals Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NRx Pharmaceuticals Inc (2017–2025)
Cash flow-to-debt ratio of NRx Pharmaceuticals Inc from 2017 to 2025. Historical debt coverage capacity for NRx Pharmaceuticals Inc across 9 annual periods. Also explore NRXPW year-over-year net asset growth to track the company's year-over-year net asset growth rate.
NRx Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
NRx Pharmaceuticals Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for NRx Pharmaceuticals Inc. For the full cash flow conversion analysis, see how efficiently does NRx Pharmaceuticals Inc generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.49x | $-14.11 Million | $28.89 Million | ▼ -23.4% |
| 2024 | -0.40x | $-10.64 Million | $26.87 Million | ▲ +65.2% |
| 2023 | -1.14x | $-21.66 Million | $19.05 Million | ▲ +47.4% |
| 2022 | -2.16x | $-39.76 Million | $18.41 Million | ▲ +31.7% |
| 2021 | -3.16x | $-37.70 Million | $11.92 Million | ▼ -6421.5% |
| 2020 | -0.05x | $-2.27 Million | $46.71 Million | ▲ +84.3% |
| 2019 | -0.31x | $-792.73K | $2.57 Million | ▲ +18.2% |
| 2018 | -0.38x | $-473.19K | $1.26 Million | ▲ +74.2% |
| 2017 | -1.46x | $-135.81K | $93.17K | — |